<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00644</drugbank-id>
  <drugbank-id>APRD01001</drugbank-id>
  <name>Gonadorelin</name>
  <description>Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pituitary.</description>
  <cas-number>33515-09-2</cas-number>
  <unii>9O7312W37G</unii>
  <average-mass>1182.2901</average-mass>
  <monoisotopic-mass>1181.573025571</monoisotopic-mass>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
    <group>vet_approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A977</ref-id>
        <pubmed-id>16373418</pubmed-id>
        <citation>Dungan HM, Clifton DK, Steiner RA: Minireview: kisspeptin neurons as central processors in the regulation of gonadotropin-releasing hormone secretion. Endocrinology. 2006 Mar;147(3):1154-8. Epub 2005 Dec 22.</citation>
      </article>
      <article>
        <ref-id>A978</ref-id>
        <pubmed-id>16621281</pubmed-id>
        <citation>Franceschini I, Lomet D, Cateau M, Delsol G, Tillet Y, Caraty A: Kisspeptin immunoreactive cells of the ovine preoptic area and arcuate nucleus co-express estrogen receptor alpha. Neurosci Lett. 2006 Jul 3;401(3):225-30. Epub 2006 Apr 18.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Rainer Uhmann, Kurt Radscheit, "Process for the low-racemization preparation of peptide intermediates of the synthesis of gonadorelin and gonadorelin analogs, and new intermediates for this process." U.S. Patent US4691008, issued December, 1984.</synthesis-reference>
  <indication>For evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.</indication>
  <pharmacodynamics>Gonadorelin is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pitutitary. In the pituitary GnRH stimulates synthesis and release of FSH and LH, a process that is controlled by the frequency and amplitude of GnRH pulses, as well as the feedback of androgens and estrogens. The pulsatility of GnRH secretion has been seen in all vertebrates, and it is necessary to ensure a correct reproductive function. Thus a single hormone, GnRH, controls a complex process of follicular growth, ovulation, and corpus luteum maintenance in the female, and spermatogenesis in the male. Its short half life requires infusion pumps for its clinical use</pharmacodynamics>
  <mechanism-of-action>Systemic - Like naturally occurring gonadotropin-releasing hormone (GnRH), gonadorelin primarily stimulates the synthesis and release of luteinizing hormone (LH) from the anterior pituitary gland. Follicle-stimulating hormone (FSH) production and release is also increased by gonadorelin, but to a lesser degree. In prepubertal females and some gonadal function disorders, the FSH response may be greater than the LH response. For the treatment of amenorrhea, delayed puberty, and infertility the administration of gonadorelin is used to simulate the physiologic release of GnRH from the hypothalamus in treatment of delayed puberty, treatment of infertility caused by hypogonadotropic hypogonadism, and induction of ovulation in those women with hypothalamic amenorrhea. This results in increased levels of pituitary gonadotropins LH and FSH, which subsequently stimulate the gonads to produce reproductive steroids.</mechanism-of-action>
  <toxicity>LD&lt;sub&gt;50&lt;/sub&gt;&gt;3000 mg/kg (rat, oral)</toxicity>
  <metabolism>Rapidly hydrolyzed to inactive peptide components</metabolism>
  <absorption>Rapidly absorbed when injected</absorption>
  <half-life>Very short, initial, 2 to 10 minutes; terminal, 10 to 40 minutes</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.</description>
    <direct-parent>Polypeptides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic Polymers</superclass>
    <class>Polypeptides</class>
    <subclass/>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>3-alkylindoles</alternative-parent>
    <alternative-parent>Alpha amino acid amides</alternative-parent>
    <alternative-parent>Amphetamines and derivatives</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboximidamides</alternative-parent>
    <alternative-parent>Guanidines</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Histidine and derivatives</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imidazoles</alternative-parent>
    <alternative-parent>Lactams</alternative-parent>
    <alternative-parent>Leucine and derivatives</alternative-parent>
    <alternative-parent>N-acyl amines</alternative-parent>
    <alternative-parent>N-acyl-alpha amino acids and derivatives</alternative-parent>
    <alternative-parent>N-acylpyrrolidines</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Peptides</alternative-parent>
    <alternative-parent>Phenylalanine and derivatives</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Primary carboxylic acid amides</alternative-parent>
    <alternative-parent>Proline and derivatives</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <alternative-parent>Pyrrolidine-2-ones</alternative-parent>
    <alternative-parent>Pyrrolidinecarboxamides</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Serine and derivatives</alternative-parent>
    <alternative-parent>Substituted pyrroles</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <alternative-parent>Tryptamines and derivatives</alternative-parent>
    <alternative-parent>Tyrosine and derivatives</alternative-parent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>2-pyrrolidone</substituent>
    <substituent>3-alkylindole</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Alpha peptide</substituent>
    <substituent>Alpha-amino acid amide</substituent>
    <substituent>Alpha-amino acid or derivatives</substituent>
    <substituent>Amphetamine or derivatives</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboximidamide</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Fatty acyl</substituent>
    <substituent>Fatty amide</substituent>
    <substituent>Guanidine</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Histidine or derivatives</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imidazole</substituent>
    <substituent>Indole</substituent>
    <substituent>Indole or derivatives</substituent>
    <substituent>Lactam</substituent>
    <substituent>Leucine or derivatives</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-acyl-alpha amino acid or derivatives</substituent>
    <substituent>N-acyl-amine</substituent>
    <substituent>N-acylpyrrolidine</substituent>
    <substituent>N-substituted-alpha-amino acid</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenol</substituent>
    <substituent>Phenylalanine or derivatives</substituent>
    <substituent>Polypeptide</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Primary carboxylic acid amide</substituent>
    <substituent>Proline or derivatives</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Pyrrole</substituent>
    <substituent>Pyrrolidine</substituent>
    <substituent>Pyrrolidine carboxylic acid or derivatives</substituent>
    <substituent>Pyrrolidine-2-carboxamide</substituent>
    <substituent>Pyrrolidone</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Serine or derivatives</substituent>
    <substituent>Substituted pyrrole</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
    <substituent>Triptan</substituent>
    <substituent>Tyrosine or derivatives</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001155</drugbank-id>
      <name>Gonadorelin acetate</name>
      <unii>2RG1XQ1NYJ</unii>
      <cas-number>52699-48-6</cas-number>
      <inchikey>OOBWZCWPKJOGPF-UHFFFAOYSA-N</inchikey>
      <average-mass>1260.378</average-mass>
      <monoisotopic-mass>1259.604719596</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT000983</drugbank-id>
      <name>Gonadorelin diacetate tetrahydrate</name>
      <unii>L8CRY8PWF2</unii>
      <cas-number/>
      <inchikey>QZBIKDNLZRFYMZ-KYOBJPNESA-N</inchikey>
      <average-mass>1374.475</average-mass>
      <monoisotopic-mass>1373.657543018</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT000982</drugbank-id>
      <name>Gonadorelin hydrochloride</name>
      <unii>3PFC574ITA</unii>
      <cas-number>51952-41-1</cas-number>
      <inchikey>CXLJLMYFZCNNQA-HBBGHHHDSA-N</inchikey>
      <average-mass>1218.77</average-mass>
      <monoisotopic-mass>1217.5497033</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">GnRH</synonym>
    <synonym language="english/german" coder="inn">Gonadorelin</synonym>
    <synonym language="spanish" coder="inn">Gonadorelina</synonym>
    <synonym language="french" coder="inn">Gonadoréline</synonym>
    <synonym language="latin" coder="inn">Gonadorelinum</synonym>
    <synonym language="english" coder="">Gonadotropin-releasing hormone</synonym>
  </synonyms>
  <products>
    <product>
      <name>Factrel Inj 0.5mg/vial</name>
      <labeller>Ayerst Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00368385</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1976-12-31</started-marketing-on>
      <ended-marketing-on>1996-09-10</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Factrel Pws 100mcg/vial</name>
      <labeller>Wyeth Ayerst Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02042096</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on>1999-10-26</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Factrel Pws 500mcg/vial</name>
      <labeller>Wyeth Ayerst Canada Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02041820</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-12-31</started-marketing-on>
      <ended-marketing-on>1999-10-26</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gonadorelin Diacetate Tetrahydrate</name>
      <labeller>NV Organon</labeller>
      <ndc-id/>
      <ndc-product-code>12860-0436</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-01-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 g/1g</strength>
      <route>Not applicable</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Lutrepulse</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02046202</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Lutrepulse Pws 0.8mg/vial</name>
      <labeller>Ferring Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02046210</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Relisorm 100 for Inj.-pws Liq-kit Sc IV</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02126699</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Relisorm 500 for Inj.-pws Liq-kit IV Sc</name>
      <labeller>Emd Serono, A Division Of Emd Inc., Canada</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02126702</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Liquid; Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Fertagyl</name>
      <company/>
    </international-brand>
    <international-brand>
      <name>Gonadorelin</name>
      <company>Intrapharm</company>
    </international-brand>
    <international-brand>
      <name>HRF</name>
      <company>Intrapharm</company>
    </international-brand>
    <international-brand>
      <name>Hypocrine</name>
      <company>Tanabe Mitsubishi Pharma</company>
    </international-brand>
    <international-brand>
      <name>Kryptocur</name>
      <company>Sanofi-Aventis</company>
    </international-brand>
    <international-brand>
      <name>Lutrelef</name>
      <company>Ferring</company>
    </international-brand>
    <international-brand>
      <name>Relefact</name>
      <company>Sanofi-Aventis</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Relisorm 500 for Inj.-pws Liq-kit IV Sc</name>
      <ingredients>Gonadorelin</ingredients>
    </mixture>
    <mixture>
      <name>Relisorm 100 for Inj.-pws Liq-kit Sc IV</name>
      <ingredients>Gonadorelin</ingredients>
    </mixture>
    <mixture>
      <name>Gonadorelin Diacetate Tetrahydrate</name>
      <ingredients>Gonadorelin</ingredients>
    </mixture>
    <mixture>
      <name>Lutrepulse Pws 0.8mg/vial</name>
      <ingredients>Gonadorelin</ingredients>
    </mixture>
    <mixture>
      <name>Factrel Pws 100mcg/vial</name>
      <ingredients>Gonadorelin</ingredients>
    </mixture>
    <mixture>
      <name>Factrel Pws 500mcg/vial</name>
      <ingredients>Gonadorelin</ingredients>
    </mixture>
    <mixture>
      <name>Factrel Inj 0.5mg/vial</name>
      <ingredients>Gonadorelin</ingredients>
    </mixture>
    <mixture>
      <name>Lutrepulse</name>
      <ingredients>Gonadorelin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Intervet International</name>
      <url>http://www.intervet.ca</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Ferring pharmaceuticals inc</manufacturer>
    <manufacturer generic="false" url="">Baxter healthcare corp anesthesia critical care</manufacturer>
  </manufacturers>
  <prices/>
  <categories>
    <category>
      <category>Adrenal Cortex Hormones</category>
      <mesh-id>D000305</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Diagnostic Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gonadotropin-releasing hormone agonist</category>
      <mesh-id>D007987</mesh-id>
    </category>
    <category>
      <category>Gonadotropin-Releasing Hormone, agonists</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gonadotropin-Releasing Hormone, antagonists &amp; inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Gonadotropins and Antigonadotropins</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Hypothalamic Hormones</category>
      <mesh-id>D007028</mesh-id>
    </category>
    <category>
      <category>Nerve Tissue Proteins</category>
      <mesh-id>D009419</mesh-id>
    </category>
    <category>
      <category>Neuropeptides</category>
      <mesh-id>D009479</mesh-id>
    </category>
    <category>
      <category>Oligopeptides</category>
      <mesh-id>D009842</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Pituitary and Hypothalamic Hormones and Analogues</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pituitary Function</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pituitary Hormone-Releasing Hormones</category>
      <mesh-id>D010906</mesh-id>
    </category>
    <category>
      <category>Proteins</category>
      <mesh-id>D011506</mesh-id>
    </category>
    <category>
      <category>Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins</category>
      <mesh-id/>
    </category>
    <category>
      <category>Tests for Fertility Disturbances</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder</form>
      <route>Not applicable</route>
      <strength>1 g/1g</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Liquid; powder, for solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="V04CM01">
      <level code="V04CM">Tests for fertility disturbances</level>
      <level code="V04C">OTHER DIAGNOSTIC AGENTS</level>
      <level code="V04">DIAGNOSTIC AGENTS</level>
      <level code="V">VARIOUS</level>
    </atc-code>
    <atc-code code="H01CA01">
      <level code="H01CA">Gonadotropin-releasing hormones</level>
      <level code="H01C">HYPOTHALAMIC HORMONES</level>
      <level code="H01">PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES</level>
      <level code="H">SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>36:66.00</ahfs-code>
    <ahfs-code>68:18.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00644.pdf?1265922750</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB09066</drugbank-id>
      <name>Corifollitropin alfa</name>
      <description>The therapeutic efficacy of Corifollitropin alfa can be increased when used in combination with Gonadorelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00089</drugbank-id>
      <name>Capromab pendetide</name>
      <description>Gonadorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09277</drugbank-id>
      <name>Choline C 11</name>
      <description>Gonadorelin may decrease effectiveness of Choline C 11 as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06404</drugbank-id>
      <name>Human C1-esterase inhibitor</name>
      <description>The risk or severity of thromboembolism can be increased when Gonadorelin is combined with Human C1-esterase inhibitor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09228</drugbank-id>
      <name>Conestat alfa</name>
      <description>The risk or severity of thromboembolism can be increased when Gonadorelin is combined with Conestat alfa.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-0.09</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.3</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.88e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-6.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>N-(1-{2-[(carbamoylmethyl)carbamoyl]pyrrolidin-1-yl}-5-[(diaminomethylidene)amino]-1-oxopentan-2-yl)-2-{2-[2-(3-hydroxy-2-{2-[3-(1H-imidazol-5-yl)-2-[(5-oxopyrrolidin-2-yl)formamido]propanamido]-3-(1H-indol-3-yl)propanamido}propanamido)-3-(4-hydroxyphenyl)propanamido]acetamido}-4-methylpentanamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>gonadotropin releasing hormone</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>1182.2901</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>1181.573025571</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CC(C)CC(NC(=O)CNC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=CC=CC=C12)NC(=O)C(CC1=CN=CN1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(N)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C55H75N17O13</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C55H75N17O13/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>XLXSAKCOAKORKW-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>474.63</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>302.51</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>121.19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>31</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>17</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>16</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>9.47</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>11.16</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>1 mg/mL</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>-3.6</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7330</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11313</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7361</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7362</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>36523</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506144</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C07607</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>33562</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA449801</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001052</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Gonadorelin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1981292</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/gonadorelin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/gonadorelin.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000203</id>
      <name>Gonadotropin-releasing hormone receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A5334</ref-id>
            <pubmed-id>15967801</pubmed-id>
            <citation>Lu ZL, Gallagher R, Sellar R, Coetsee M, Millar RP: Mutations remote from the human gonadotropin-releasing hormone (GnRH) receptor-binding sites specifically increase binding affinity for GnRH II but not GnRH I: evidence for ligand-selective, receptor-active conformations. J Biol Chem. 2005 Aug 19;280(33):29796-803. Epub 2005 Jun 20.</citation>
          </article>
          <article>
            <ref-id>A5335</ref-id>
            <pubmed-id>16962597</pubmed-id>
            <citation>Moles G, Carrillo M, Mananos E, Mylonas CC, Zanuy S: Temporal profile of brain and pituitary GnRHs, GnRH-R and gonadotropin mRNA expression and content during early development in European sea bass (Dicentrarchus labrax L.). Gen Comp Endocrinol. 2007 Jan 1;150(1):75-86. Epub 2006 Sep 8.</citation>
          </article>
          <article>
            <ref-id>A5336</ref-id>
            <pubmed-id>16973761</pubmed-id>
            <citation>Mamputha S, Lu ZL, Roeske RW, Millar RP, Katz AA, Flanagan CA: Conserved amino acid residues that are important for ligand binding in the type I gonadotropin-releasing hormone (GnRH) receptor are required for high potency of GnRH II at the type II GnRH receptor. Mol Endocrinol. 2007 Jan;21(1):281-92. Epub 2006 Sep 14.</citation>
          </article>
          <article>
            <ref-id>A5337</ref-id>
            <pubmed-id>17002488</pubmed-id>
            <citation>Lee PA, Houk CP: Gonadotropin-releasing hormone analog therapy for central precocious puberty and other childhood disorders affecting growth and puberty. Treat Endocrinol. 2006;5(5):287-96.</citation>
          </article>
          <article>
            <ref-id>A5338</ref-id>
            <pubmed-id>17068198</pubmed-id>
            <citation>Bliss SP, Navratil AM, Breed M, Skinner DC, Clay CM, Roberson MS: Signaling complexes associated with the type I gonadotropin-releasing hormone (GnRH) receptor: colocalization of extracellularly regulated kinase 2 and GnRH receptor within membrane rafts. Mol Endocrinol. 2007 Feb;21(2):538-49. Epub 2006 Oct 26.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P30968" source="Swiss-Prot">
        <name>Gonadotropin-releasing hormone receptor</name>
        <general-function>Peptide binding</general-function>
        <specific-function>Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This receptor mediates its action by association with G-proteins that activate a phosphatidylinositol-calcium second messenger system. Isoform 2 may act as an inhibitor of GnRH-R signaling.</specific-function>
        <gene-name>GNRHR</gene-name>
        <locus>4q21.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>39-58
78-97
116-137
165-184
213-232
282-300
307-326</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.93</theoretical-pi>
        <molecular-weight>37730.355</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4421</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GNRHR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L03380</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>183422</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>256</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>256</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P30968</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GNRHR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GnRH receptor</synonym>
          <synonym>GRHR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000405|Gonadotropin-releasing hormone receptor
MANSASPEQNQNHCSAINNSIPLMQGNLPTLTLSGKIRVTVTFFLFLLSATFNASFLLKL
QKWTQKKEKGKKLSRMKLLLKHLTLANLLETLIVMPLDGMWNITVQWYAGELLCKVLSYL
KLFSMYAPAFMMVVISLDRSLAITRPLALKSNSKVGQSMVGLAWILSSVFAGPQLYIFRM
IHLADSSGQTKVFSQCVTHCSFSQWWHQAFYNFFTFSCLFIIPLFIMLICNAKIIFTLTR
VLHQDPHELQLNQSKNNIPRARLKTLKMTVAFATSFTVCWTPYYVLGIWYWFDPEMLNRL
SDPVNHFFFLFAFLNPCFDPLIYGYFSL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0018926|Gonadotropin-releasing hormone receptor (GNRHR)
ATGGCAAACAGTGCCTCTCCTGAACAGAATCAAAATCACTGTTCAGCCATCAACAACAGC
ATCCCACTGATGCAGGGCAACCTCCCCACTCTGACCTTGTCTGGAAAGATCCGAGTGACG
GTTACTTTCTTCCTTTTTCTGCTCTCTGCGACCTTTAATGCTTCTTTCTTGTTGAAACTT
CAGAAGTGGACACAGAAGAAAGAGAAAGGGAAAAAGCTCTCAAGAATGAAGCTGCTCTTA
AAACATCTGACCTTAGCCAACCTGTTGGAGACTCTGATTGTCATGCCACTGGATGGGATG
TGGAACATTACAGTCCAATGGTATGCTGGAGAGTTACTCTGCAAAGTTCTCAGTTATCTA
AAGCTTTTCTCCATGTATGCCCCAGCCTTCATGATGGTGGTGATCAGCCTGGACCGCTCC
CTGGCTATCACGAGGCCCCTAGCTTTGAAAAGCAACAGCAAAGTCGGACAGTCCATGGTT
GGCCTGGCCTGGATCCTCAGTAGTGTCTTTGCAGGACCACAGTTATACATCTTCAGGATG
ATTCATCTAGCAGACAGCTCTGGACAGACAAAAGTTTTCTCTCAATGTGTAACACACTGC
AGTTTTTCACAATGGTGGCATCAAGCATTTTATAACTTTTTCACCTTCAGCTGCCTCTTC
ATCATCCCTCTTTTCATCATGCTGATCTGCAATGCAAAAATCATCTTCACCCTGACACGG
GTCCTTCATCAGGACCCCCACGAACTACAACTGAATCAGTCCAAGAACAATATACCAAGA
GCACGGCTGAAGACTCTAAAAATGACGGTTGCATTTGCCACTTCATTTACTGTCTGCTGG
ACTCCCTACTATGTCCTAGGAATTTGGTATTGGTTTGATCCTGAAATGTTAAACAGGTTG
TCAGACCCAGTAAATCACTTCTTCTTTCTCTTTGCCTTTTTAAACCCATGCTTTGATCCA
CTTATCTATGGATATTTTTCTCTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>gonadotropin-releasing hormone receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptide binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to gonadotropin-releasing hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multicellular organismal development</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0000472</id>
      <name>Putative gonadotropin-releasing hormone II receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A10744</ref-id>
            <pubmed-id>16916952</pubmed-id>
            <citation>Morgan K, Sellar R, Pawson AJ, Lu ZL, Millar RP: Bovine and ovine gonadotropin-releasing hormone (GnRH)-II ligand precursors and type II GnRH receptor genes are functionally inactivated. Endocrinology. 2006 Nov;147(11):5041-51. Epub 2006 Aug 17.</citation>
          </article>
          <article>
            <ref-id>A5336</ref-id>
            <pubmed-id>16973761</pubmed-id>
            <citation>Mamputha S, Lu ZL, Roeske RW, Millar RP, Katz AA, Flanagan CA: Conserved amino acid residues that are important for ligand binding in the type I gonadotropin-releasing hormone (GnRH) receptor are required for high potency of GnRH II at the type II GnRH receptor. Mol Endocrinol. 2007 Jan;21(1):281-92. Epub 2006 Sep 14.</citation>
          </article>
          <article>
            <ref-id>A10745</ref-id>
            <pubmed-id>16712461</pubmed-id>
            <citation>Montagnani Marelli M, Moretti RM, Januszkiewicz-Caulier J, Motta M, Limonta P: Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients? Curr Cancer Drug Targets. 2006 May;6(3):257-69.</citation>
          </article>
          <article>
            <ref-id>A10746</ref-id>
            <pubmed-id>15635044</pubmed-id>
            <citation>Li JH, Choe H, Wang AF, Maiti K, Wang C, Salam A, Chun SY, Lee WK, Kim K, Kwon HB, Seong JY: Extracellular loop 3 (EL3) and EL3-proximal transmembrane helix 7 of the mammalian type I and type II gonadotropin-releasing hormone (GnRH) receptors determine differential ligand selectivity to GnRH-I and GnRH-II. Mol Pharmacol. 2005 Apr;67(4):1099-110. Epub 2005 Jan 5.</citation>
          </article>
          <article>
            <ref-id>A10747</ref-id>
            <pubmed-id>16720727</pubmed-id>
            <citation>Silver MR, Sower SA: Functional characterization and kinetic studies of an ancestral lamprey GnRH-III selective type II GnRH receptor from the sea lamprey, Petromyzon marinus. J Mol Endocrinol. 2006 Jun;36(3):601-10.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q96P88" source="Swiss-Prot">
        <name>Putative gonadotropin-releasing hormone II receptor</name>
        <general-function>Gonadotropin-releasing hormone receptor activity</general-function>
        <specific-function>Putative receptor for gonadotropin releasing hormone II (GnRH II) which is most probably non-functional.</specific-function>
        <gene-name>GNRHR2</gene-name>
        <locus>1q12</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>29-49
68-88
116-136
178-198
217-237</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.68</theoretical-pi>
        <molecular-weight>32536.935</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:16341</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GNRHR2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF403014</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>16589056</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>257</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q96P88</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GNRR2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GnRH II receptor</synonym>
          <synonym>Type II GnRH receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037024|Putative gonadotropin-releasing hormone II receptor
MSAGNGTPWDATWNITVQWLAVDIACRTLMFLKLMATYSAAFLPVVIGLDRQAAVLNPLG
SRSGVRKLLGAAWGLSFLLAFPQLFLFHTVHCAGPVPFTQCVTKGSFKAQWQETTYNLFT
FCCLFLLPLTAMAICYSRIVLSVSRPQTRKGSHAPAGEFALPRSFDNCPRVRLRALRLAL
LILLTFILCWTPYYLLGMWYWFSPTMLTEVPPSLSHILFLLGLLNAPLDPLLYGAFTLGC
RRGHQELSIDSSKEGSGRMLQEEIHAFRQLEVQKTVTSRRAGETKGISITSI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0000942|1140 bp
CATGTCTGCAGGCAACGGCACCCCTTGGGGTCAGCAGCGGGGGAGGAGGTCTGGGCTGGA
TCAGGAGTGGAGGTGGAGGGCTCAGAGCTGCCCACCTTCTCGGCAGCAGCCAAGGTCCGA
GTGGGAGTGACCATTGTGCTGTTTGTTTCTTCGGCTGGAGGGAACCTGGCAGTCCTGTGG
TCAGTGACACGGCGGGAACCCAGCCAGCTCCGCCCCTCTCCGGTCAGGAGACTCTTCATC
CATTTAGCAGCCGCCGACTTACTAGTCACTTTTGTGGTTATGCCCCTAGATGCCACCTGG
AATATCACTGTTCAATGGCTGGCTGTGGACATCGCATGTCGGACACTGATGTTCCTGAAA
CTAATGGCCACGTATTCTGCAGCTTTCCTGCCTGTGGTCATTGGATTGGACCGCCAGGCA
GCAGTACTCAACCCGCTTGGATCCCGTTCAGGTGTAAGGAAACTTCTGGGGGCAGCCTGG
GGACTTAGTTTCCTGCTTGCCTTCCCCCAGCTGTTCCTGTTCCACACGGTCCACTGAGCT
GGCCCAGTCCCTTTCACTCAGTGTGTCACCAAAGGCAGCTTCAAGGCTCAATGGCAAGAG
ACCACCTATAACCTCTTCACCTTCTGCTGCCTCTTTCTGCTGCCACTGACTGCCATGGCC
ATCTGCTATAGCCGCATTGTCCTCAGTGTGTCCAGGCCCCAGACAAGGAAGGGGAGCCAT
GCCCCTGCTGGTGAATTTGCCCTCCCCCGCTCCTTTGACAATTGTCCCCGTGTTCGTCTC
CGGGCCCTGAGACTGGCCCTGCTTATCTTGCTGACCTTCATCCTCTGCTGGACACCTTAT
TACCTACTGGGTATGTGGTACTGGTTCTCCCCCACCATGCTAACTGAAGTCCCTCCCAGC
CTGAGCCACATCCTTTTCCTCTTGGGCCTCCTCAATGCTCCTTTGGATCCTCTCCTCTAT
GGGGCCTTCACCCTTGGCTGCCGAAGAGGGCACCAAGAACTTAGTATAGACTCTTCTAAA
GAAGGGTCTGGGAGAATGCTCCAAGAGGAGATTCATGCCTTTAGACAGCTGGAAGTACAA
AAAACTGTGACATCAAGAAGGGCAGGAGAAACAAAAGGCATTTCTATAACATCTATCTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>gonadotropin-releasing hormone receptor activity</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>